Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Wegovy by Novo Nordisk for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Wegovy is under clinical development by Novo Nordisk and currently in Pre-Registration for Diastolic Heart Failure (HFpEF). According to GlobalData,...
Cagrilintide by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
Cagrilintide is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
NNC-04870111 by Novo Nordisk for Obesity: Likelihood of Approval
NNC-04870111 is under clinical development by Novo Nordisk and currently in Phase II for Obesity. According to GlobalData, Phase II...
Ziltivekimab by Novo Nordisk for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to...
NN-9542 by Novo Nordisk for Diabetes: Likelihood of Approval
NN-9542 is under clinical development by Novo Nordisk and currently in Phase I for Diabetes. According to GlobalData, Phase I...
NN-4002 by Novo Nordisk for Solid Tumor: Likelihood of Approval
NN-4002 is under clinical development by Novo Nordisk and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
NN-4002 by Novo Nordisk for Non-Hodgkin Lymphoma: Likelihood of Approval
NN-4002 is under clinical development by Novo Nordisk and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
NNC0519-0130 by Novo Nordisk for Obesity: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Obesity. According to GlobalData, Phase II...
NN-9499 by Novo Nordisk for Liver Diseases: Likelihood of Approval
NN-9499 is under clinical development by Novo Nordisk and currently in Phase II for Liver Diseases. According to GlobalData, Phase...
NNC-06500013 by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
NNC-06500013 is under clinical development by Novo Nordisk and currently in Phase I for Type 2 Diabetes. According to GlobalData,...
NN-9041 by Novo Nordisk for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
NN-9041 is under clinical development by Novo Nordisk and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According...
NNC0519-0130 by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
NN-6491 by Novo Nordisk for Dyslipidemia: Likelihood of Approval
NN-6491 is under clinical development by Novo Nordisk and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I...
Lefelsiran sodium by Novo Nordisk for Alcohol Dependence: Likelihood of Approval
Lefelsiran sodium is under clinical development by Novo Nordisk and currently in Phase I for Alcohol Dependence. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Monlunabant?
Monlunabant is a small molecule commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Lefelsiran Sodium?
Lefelsiran Sodium is an antisense rnai oligonucleotide commercialized by Novo Nordisk, with a leading Phase I program in Alcohol Dependence....
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Denecimig?
Denecimig is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's (Insulin icodec + Semaglutide)?
(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Cagrisema?
Cagrisema is a recombinant peptide and synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program in Type...
Etavopivat by Novo Nordisk for Anemia: Likelihood of Approval
Etavopivat is under clinical development by Novo Nordisk and currently in Phase II for Anemia. According to GlobalData, Phase II...